Phase 3 Muscular Dystrophy Trial, Recruiting (NCT07160634)

Phase 3 Muscular Dystrophy Trial, Recruiting NCT07160634 Sponsor: Solid Biosciences Inc. Condition: Muscular Dystrophy

Printed from Voxsanity (voxsanity.com.au) — NCT07160634 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Muscular Dystrophy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are able to walk on your own.
You have a confirmed diagnosis of Duchenne muscular dystrophy (DMD) and a genetic test has identified a specific DMD gene change linked to the condition.
A blood test shows you do not have antibodies against a common virus called adeno-associated virus (AAV).
You have been taking a steady daily dose of a steroid medication (either prednisone or deflazacort) for at least 6 months before joining the study.
You meet certain time requirements for walking or running 10 meters (confirm with trial site).
You meet certain time requirements for getting up from a lying-down position (confirm with trial site).
You weigh 50 kilograms (about 110 pounds) or less.

Who may not be able to join:

You have previously received, or are currently receiving, any gene therapy or gene editing treatment, whether approved or experimental.
You have taken certain specific DMD-related or experimental medications — including vamorolone, givinostat, eteplirsen, golodirsen, casimersen, viltolarsen, or ataluren — within roughly the past 6 months or longer.
Your specific type of DMD gene change falls into certain categories that affect particular sections of the DMD gene (confirm with trial site which gene variants are excluded).

Other eligibility requirements not listed here may also apply, as described in the full study protocol.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 6173374680

Australian sites

The Children's Hospital of Westmead, Sydney, New South Wales
(02) 7825 1387

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07160634

Sponsor: Solid Biosciences Inc.

Phase: Phase 3

Status: Recruiting

Condition: Muscular Dystrophy

Trial contact: 6173374680

More information: https://clinicaltrials.gov/study/NCT07160634

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are able to walk on your own.
You have a confirmed diagnosis of Duchenne muscular dystrophy (DMD) and a genetic test has identified a specific DMD gene change linked to the condition.
A blood test shows you do not have antibodies against a common virus called adeno-associated virus (AAV).
You have been taking a steady daily dose of a steroid medication (either prednisone or deflazacort) for at least 6 months before joining the study.
You meet certain time requirements for walking or running 10 meters (confirm with trial site).
You meet certain time requirements for getting up from a lying-down position (confirm with trial site).
You weigh 50 kilograms (about 110 pounds) or less.

Who may not be able to join:

You have previously received, or are currently receiving, any gene therapy or gene editing treatment, whether approved or experimental.
You have taken certain specific DMD-related or experimental medications — including vamorolone, givinostat, eteplirsen, golodirsen, casimersen, viltolarsen, or ataluren — within roughly the past 6 months or longer.
Your specific type of DMD gene change falls into certain categories that affect particular sections of the DMD gene (confirm with trial site which gene variants are excluded).

Other eligibility requirements not listed here may also apply, as described in the full study protocol.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Solid Biosciences Inc.

Registry

ClinicalTrials.gov

Start date

22 October 2025

Est. completion

1 January 2029

Where this trial is recruiting

🇦🇺 Australia 🇨🇦 Canada 🇺🇸 United States

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Change From Baseline in Time to Rise (TTR) from Supine Velocity (rise/s) at Day 540

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov